Antibody Drug Conjugates (ADC): FRalpha
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Antibody Drug Conjugates (ADC): HER2
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Antibody Drug Conjugates (ADC): CLDN6
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Antibody Drug Conjugates (ADC): CDH6
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Antibody Drug Conjugates (ADC): B7H4
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Antibody Drug Conjugates (ADC): FRalpha
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02606305; FORWARD II | Ib/II | Bevacizumab, Carboplatin, Mirvetuximab soravtansine | A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer | Encouraging activity of mirvetuximab soravtansine combinations in FRalpha+ patients Mir+CarboPt: ORR: 71% Mir+CarboPt+Bev: 1-2 prior therapies: 1 prior therapy: pub 2018, abs Oct 2020 |
| NCT02606305; FORWARD II | Ib/II | Carboplatin, Mirvetuximab soravtansine | A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer | The combination of carboplatin and mirvetuximab shows encouraging activity in FRalpha+ platinum sensitive patients ORR: 71% pub 2018, abs Oct 2020 |
| NCT02606305; FORWARD II-2 | Ib/II | Bevacizumab, Mirvetuximab soravtansine | A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer | The combination of mirvetuximab soravtansine with bevacizumab demonstrates an encouraging ORR in platinum sensitive patients with high FRalpha expression ORR: 69% abs Jun 2021 and presentation, Sep 2022 presentation |
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Standard of Care Targeted Drugs | ||||
| NCT04209855; MIRASOL | III | Liposomal doxorubicin, Mirvetuximab soravtansine, Paclitaxel, Topotecan | MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | Mirvetuximab soravtansine is the first treatment to demonstrate a PFS and OS benefit in Pt-R OC compared to single agent chemotherapy ORR: 42 vs 16%* pub 2023 |
| NCT04296890; SORAYA | III | Mirvetuximab soravtansine Prescribing Information | SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | Mirvetuximab shows impressive activity and tolerability in FRα-high platinum resistant ovarian cancer ORR: 32.4% pub 2023, abs Mar 2023 and presentation |
| Drugs in NCCN Guidelines | ||||
| NCT02606305; FORWARD II | Ib/II | Bevacizumab, Mirvetuximab soravtansine | A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer | The mirvetuximab soravtansine plus bevacizumab doublet is an active and well-tolerated regimen in patients with FRα-expressing platinum-resistant ovarian cancer. Promising activity is observed for patients regardless of level of FRα expression or prior bevacizumab ORR: 44% pub 2023 |
| Drugs in Clinical Development | ||||
| NCT02631876; FORWARD I | III | Liposomal doxorubicin, Mirvetuximab soravtansine, Paclitaxel, Topotecan | FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer | Mirvetuximab soravtansine has favorable tolerability and benefit-risk profile compared to chemotherapy in FRalpha high patients Mir vs TPC (PLD, Pac, Top): FRalpha high (10X scoring method): ORR: 24 vs 10%* FRalpha high (PS2+ scoring method): ORR: 26 vs 6%* pub 2021 |
| NCT02606305; FORWARD II | Ib/II | Liposomal doxorubicin, Pembrolizumab, Bevacizumab, Mirvetuximab soravtansine | A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer | Encouraging activity of mirvetuximab soravtansine with bevacizumab, liposomal doxorubicin or pembrolizumab in FRalpha+ patients Mir+Bev: abs May 2017, abs Apr 2018, pub 2020 |
| NCT01609556 | I | Mirvetuximab soravtansine | A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors | Mirvetuximab soravtansine shows promising activity in platinum-resistant FRalpha+ patients who had ≤3 prior therapies ≤3 prior therapies vs >3 prior therapies: ORR: 39 vs 13% pub 2017; abs Jun 2017 |
| NCT02996825 | I | Mirvetuximab soravtansine, Gemcitabine | A Phase I Dose-Escalation Safety and Tolerability Study of MirvetuximabSoravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC) | Mirvetuximab soravtansine and gemcitabine demonstrate promising activity in platinum resistant ovarian cancer, but with frequent hematologic toxicities ORR: 40.9% abs Jun 2021 and poster, pub 2024 |
| NCT03386942 | I | Farletuzumab ecteribulin | A Phase 1 Study of MORAb-202 in Subjects With Solid Tumors | Anti-tumor activity is seen with both the farletuzumab ecteribulin (MORAb-202) 0.9 mg/kg and 1.2 mg/kg doses and efficacy is observed irrespective of FRalpha-expression levels 0.9 mg/kg (n=24): ORR: 25% 1.2 mg/kg (n=21) ORR: 52.4% Abs Jun 2022 and posters |
| NCT03748186 | I | Luveltamab tazevibulin | A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers | Luveltamab tazevibulin (STRO-002) is well tolerated with evidence of anti-tumor activity in heavily pretreated patients across a broad range of FRα expression levels. No ocular toxicity signals have been observed. All patients: FR alpha TPS > 25%: abs Jun 2021 and poster, abs Jun 2023 and presentation |
Antibody Drug Conjugates (ADC): HER2
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Standard of Care Targeted Drugs | ||||
| NCT04482309; DESTINY-PanTumor02 | II | Trastuzumab deruxtecan Prescribing Information | A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) | Trastuzumab Deruxtecan (T-DXd) has a manageable safety profile and shows encouraging ORR and durable clinical benefit in OC patients with HER2 IHC 3+ expression ORR: 63.6% (n=11) abs Oct 2023, pub 2024 |
| Drugs in NCCN Guidelines | ||||
| NCT04482309; DESTINY-PanTumor02 | II | Trastuzumab deruxtecan | A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) | Trastuzumab Deruxtecan (T-DXd) has a manageable safety profile and shows encouraging activity in OC patients with HER2 IHC 2+ ORR: 36.8% abs Oct 2023, pub 2024 |
Antibody Drug Conjugates (ADC): CLDN6
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT05103683 | I | TORL-1-23 | A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer | TORL-1-23 has a favorable safety/tolerability profile with encouraging preliminary anti-tumor activity in heavily-pretreated CLDN6-expressing ovarian cancer ORR: 33.3% Doses of 2.4 mg/kg or 3.0 mg/kg: (n=12) abs Oct 2023 and poster, press release Jan 2024 |
Antibody Drug Conjugates (ADC): CDH6
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT04707248 | I | Raludotatug deruxtecan | Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors | Raludotatug deruxtecan (DS-6000a) is generally well tolerated and demonstrates encouraging clinical activity in heavily pretreated Pt-R OC without CDH6 preselection abs Oct 2023 and presentation |
Antibody Drug Conjugates (ADC): B7H4
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT05194072 | I | Felmetatug vedotin | A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors | Felmetatug vedotin (SGN-B7H4V) shows a manageable safety profile and durable responses are observed in high grade serous OC ORR: 20% abs Oct 2023 and presentation |